• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

NPT520-34

A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

May 17, 2019

https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

DESCRIPTION:
Condition:   Healthy Volunteers
Interventions:   Drug: NPT520-34 (125 mg);   Drug: Placebos (125 mg)
Sponsors:   Neuropore Therapies Inc.;   Celerion
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03954600

FIRST POSTED:
Fri, 17 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/17/19 07:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research